FSD Pharma appoints Zeeshan Saeed as CEO
HUGEDelisted Stock | USD 0.09 0 4.56% |
About 61% of FSD Pharma's investor base is looking to short. The analysis of current outlook of investing in FSD Pharma Class suggests that many traders are alarmed regarding FSD Pharma's prospects. The current market sentiment, together with FSD Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use FSD Pharma Class stock news signals to limit their universe of possible portfolio assets.
FSD |
FSD Pharma Co-Founder and President Zeeshan Saeed to succeed Anthony Durkacz, who has been serving as the Interim CEO since July 2021.Mr. Durkacz and Mr
Read at seekingalpha.com
FSD Pharma Fundamental Analysis
We analyze FSD Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of FSD Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of FSD Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
FSD Pharma is currently under evaluation in target price category among its peers.
FSD Pharma Class Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with FSD Pharma stock to make a market-neutral strategy. Peer analysis of FSD Pharma could also be used in its relative valuation, which is a method of valuing FSD Pharma by comparing valuation metrics with similar companies.
Peers
FSD Pharma Related Equities
LEEEF | Leef Brands | 6.25 | ||||
BFRI | Biofrontera | 1.89 | ||||
LOVFF | Cannara Biotech | 4.00 | ||||
MKGAF | MERCK Kommanditgesells | 4.77 | ||||
SXTC | China SXT | 5.13 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in FSD Stock
If you are still planning to invest in FSD Pharma Class check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the FSD Pharma's history and understand the potential risks before investing.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
CEOs Directory Screen CEOs from public companies around the world | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |